SARS-CoV-2 Variant Inhibitor Screening Kit

Name: SARS-CoV-2 Variant Inhibitor Screening Kit
Brand: R&D Systems
SKU: VANC00B

Catalog # VANC00B | R&D Systems, Inc. a Bio-Techne Brand

Product Datasheet / COA / SDS

COVID-19
Now with Omicron and Delta Variant!

Setting the standard in quality research reagents

Key Product Details

Assay Type:

ELISA Type Binding Assay

Sample Types:

Cell Lysates

SARS-CoV-2 Variant Inhibitor Screening Kit Features:

Product Features

Quickly and efficiently evaluates the effectiveness of vaccines against SARS-CoV-2 variants
Can be used for high throughput screening SARS-CoV-2 inhibitors
Validated step by step assay protocol
No special equipment needed

Background: Severe acute respiratory syndrome Coronavirus-2

Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19, has posed a serious threat to global human health. With the emergence of variants, especially the Variants of Concern (VOCs), a quick and effective way to assess how effective the current vaccines are against the major variants is needed. The COVID-19 Neutralization Kit is an ELISA type of binding assay measuring the ability of the sera of vaccinated donors to block the binding between RBDs of COVID-19 variants and human ACE-2.

See the Data: Read our white paper on testing individual serum samples using this kit. Download White Paper

Assay Workflow: 5 Simple Steps

Schematic Diagram of SARS-CoV-2 Spike ACE-2 Competition ELISA using sera from COVID-19 infected and vaccinated individuals

View Full Diagram

View Full Technical Details for SARS-CoV-2 Variant Inhibitor Screening Kit

Technical Data
Citations / Reviews

Summary for SARS-CoV-2 Variant Inhibitor Screening Kit

This SARS-CoV-2 Variant Inhibitor Screening Kit contains the basic components required to measure the ability of the sera of vaccinated donors to block the binding between RBDs of COVID-19 variants and human ACE-2. The suggested diluent is suitable for the analysis of most serum and plasma samples.

Product Specifications for SARS-CoV-2 Variant Inhibitor Screening Kit

Assay Format	96-well strip plate (sold separately)
Reactivity	SARS-CoV-2
Specificity	Please see the product datasheet
Detection Method	Colorimetric ELISA - 450nm (TMB)
Conjugate	Biotin
Label	HRP
Measurement	Quantitative ELISA
Sufficient Materials	For five 96-well plates* Provided that the recommended microplates, buffers, diluents, substrates, and solutions are used, and the assay is run as summarized in the Assay Procedure provided.

* Provided that the recommended microplates, buffers, diluents, substrates and solutions are used, and the assay is run as summarized in the Assay Procedure provided.

Kit Contents for SARS-CoV-2 Variant Inhibitor Screening Kit

Capture Antibody
SARS-Cov-2 Spike RBD Wild Type
SARS-CoV-2 Spike RBD Variants (Alpha, Beta, Gamma, Delta and Omicron)
Biotinylated Human ACE-2
Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)

Other Reagents Required

DuoSet Ancillary Reagent Kit 2 (5 plates):(Catalog # DY008) containing 96 well microplates, plate sealers, substrate solution, stop solution, plate coating buffer (PBS), wash buffer, and Reagent Diluent Concentrate 2.

The components listed above may be purchased separately:

PBS:(Catalog # DY006), or 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2 - 7.4, 0.2 µm filtered

Wash Buffer:(Catalog # WA126), or 0.05% Tween® 20 in PBS, pH 7.2-7.4

Reagent Diluent: (Catalog # DY995), or 1% BSA in PBS, pH 7.2-7.4, 0.2 µm filtered

Substrate Solution:1:1 mixture of Color Reagent A (H2O2) and Color Reagent B (Tetramethylbenzidine) (Catalog # DY999)

Stop Solution:2 N H2SO4 (Catalog # DY994)

Microplates:R&D Systems (Catalog # DY990)

Plate Sealers:ELISA Plate Sealers (Catalog # DY992)

Scientific Data Examples for SARS-CoV-2 Variant Inhibitor Screening Kit

	Figure 1: Example data using vaccinated donor samples. Serological samples were collected from two donors over a time course consisting Pre-Vaccination (Pre-Vac), or after receiving the 1st Dose or 2nd Dose of the Moderna Vaccine. Donor 1 (A-C) and Donor 2 (D-F) had different blocking antibody levels after the first and second doses. In addition, increasing amounts of blocking antibodies were present at higher samples Dilution Factors after each dose. The differences in blocking efficiency of ACE-2 association between the WT, Alpha, Beta, Gamma, or Delta variant Spike RBD was measured.
	Figure 2: Example data using vaccinated donor samples Using the Wild Type or the Delta and Omicron Variants. Plasma samples were collected from two donors over a time course consisting of Pre-Vaccination (Pre-Vac), or after receiving the 1st Dose or 2nd Dose of the Moderna Vaccine. Donor 1 (A-C) and Donor 2 (D-F) had different blocking antibody levels after the first and second doses. In addition, increasing amounts of blocking antibodies were present at higher samples Dilution Factors after each dose. The differences in blocking efficiency of ACE-2 association between the WT, Delta, or Omicron variant Spike RBD was measured.

Preparation and Storage

Stability & Storage

Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Spike RBD

The coronavirus Spike protein receptor binding domain (RBD) resides within the S1 subunit and is responsible for binding to host cell receptors and initiating viral infection. Past coronaviruses SARS and MERS along with the global pandemic caused by SARS-CoV-2 have sparked great interest and scientific discovery leading to new vaccines and drug development. At the heart of coronavirus biology lies the Spike protein and its receptor binding domain. The Spike RBD is a 26 kDa domain consisting of a twisted five-stranded antiparallel beta sheet and sits at the apex of each Spike protein monomer. The Spike RBD is flexible thanks to a hinge region that allows for conformational changes that expose (up or open conformation) or hide (down or closed conformation) its receptor contacts. For SARS-CoV-2, the Spike RBD recognizes and tightly binds to the human receptor ACE-2. In the closely related MERS coronavirus, human DPPIV/CD26 acts as the receptor.

Item	Value
Long Name	Spike Receptor Binding Domain
Entrez Gene IDs	3200426 (HCoV-HKU1); 14254594 (MERS-CoV); 1489668 (SARS-CoV); 43740568 (SARS-CoV-2)
Alternate Names	Spike RBD

Citations for SARS-CoV-2 Variant Inhibitor Screening Kit

Please visit our Instrument Citation Database to search our collection of scientific articles that feature our instruments.

Product Documents for SARS-CoV-2 Variant Inhibitor Screening Kit

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS